- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07842575
DEVELOPMENT AND VALIDATION OF THE URINARY INCONTINENCE KINESIOPHOBIA SEVERITY SCALE
Development of the Kinesiophobia Severity Scale in Urinary Incontinence: A Validity and Reliability Study
This study aims to develop and validate a novel Turkish-language self-report instrument, the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI), to assess movement avoidance and fear of movement associated with concerns about urinary leakage in individuals with urinary incontinence. Following scale development, its validity and reliability will be evaluated through psychometric analyses in accordance with the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations.
Study Overview
Status
Conditions
Detailed Description
This methodological study aims to develop and evaluate the validity and reliability of the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI), a novel Turkish-language self-report instrument designed to assess fear of movement and movement avoidance associated with concerns about urinary leakage.
The study will include individuals with urinary incontinence, including stress, urgency, and mixed urinary incontinence. Participants will be recruited exclusively from individuals reporting urinary incontinence among relatives of patients attending the Physical Therapy and Rehabilitation Center. Individuals who meet the eligibility criteria and voluntarily agree to participate will be enrolled in the study. Written informed consent will be obtained from all participants before data collection.
Initially, an item pool was developed through a comprehensive literature review, semi-structured interviews with 15-20 individuals with urinary incontinence, and recommendations from experts in relevant clinical disciplines. Following ethical approval, the items will undergo content validity assessment by a multidisciplinary panel of at least 10 experts. Item relevance, clarity, simplicity, and necessity will be evaluated using the Content Validity Ratio (CVR), Content Validity Index (CVI), and modified kappa statistics.
Subsequently, face validity and comprehensibility will be assessed through cognitive interviews with 8-12 individuals. Items will be revised based on participant feedback. Pilot testing will be conducted to examine item distributions, floor and ceiling effects, corrected item-total correlations, internal consistency, and item discrimination.
Following these preliminary evaluations, the revised scale will be administered to eligible participants during a single assessment session. Questionnaire completion is expected to take approximately 15-20 minutes.
Psychometric analyses will be performed to evaluate the validity and reliability of the scale. Based on the findings, the final scale will be established, and a scoring and interpretation guide will be developed.
The study is expected to provide a valid and reliable instrument for assessing urinary incontinence-related kinesiophobia and contribute to the evaluation of movement-related fear and avoidance behaviors in individuals with urinary incontinence.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Esra BAYRAMOĞLU DEMİRDÖĞEN
- Phone Number: 05426961169
- Email: esra.bayramoglu@ahievran.edu.tr
Study Contact Backup
- Name: Esra BAYRAMOĞLU DEMİRDÖĞEN
- Phone Number: 5426961169
- Email: esra.bayramoglu@ahievran.edu.tr
Study Locations
-
-
Kırşehir
-
Kırşehir, Kırşehir, Turkey (Türkiye), 40100
- Recruiting
- Kırşehir Ahi Evran Üniversitesi
-
Contact:
- Esra BAYRAMOĞLU DEMİRDÖĞEN
- Email: esra.bayramoglu@ahievran.edu.tr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will consist of adults aged 18 years or older who report urinary incontinence, including stress, urgency, and mixed urinary incontinence. Participants will be recruited from among relatives of patients attending the Physical Therapy and Rehabilitation Center. Eligible individuals who report urinary leakage at least once per week during the past three months, are able to read and understand Turkish, and voluntarily agree to participate will be included in the study. Individuals with active lower urinary tract infections or conditions that prevent independent completion of the questionnaires will be excluded.
Description
Inclusion Criteria:
- Being 18 years of age or older
- Reporting symptoms of incontinence at least once a week for the past 3 months (ICIQ-SF score ≥ 1)
- Having the ability to read and comprehend Turkish
- Having been informed about the study and provided written informed consent
Exclusion Criteria:
- Having an active lower urinary tract infection
- Inability to complete the scales independently due to cognitive impairment, advanced dementia, or limited literacy
- Individuals who refuse to participate in the study or do not sign the informed consent form
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
|---|
|
Incontinance
This group will consist of individuals with urinary incontinence, including stress, urgency, and mixed urinary incontinence, who are recruited from among relatives of patients attending the Physical Therapy and Rehabilitation Center. Eligible participants who voluntarily agree to participate will complete the newly developed Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI) to assess fear of movement and movement avoidance associated with concerns about urinary leakage. The scale will undergo psychometric evaluation to assess its validity and reliability. No therapeutic intervention will be administered as part of the study. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Content Validity of the Kinesiophobia Severity Scale in Urinary Incontinence (KSS-UI)
Time Frame: During the initial expert evaluation, before participant recruitment for the main validation study.
|
The content validity of the newly developed scale will be evaluated by a multidisciplinary panel of at least 10 experts. Item relevance, clarity, simplicity, and necessity will be assessed using the Content Validity Ratio (CVR), Item-level Content Validity Index (I-CVI), Scale-level Content Validity Index (S-CVI), and modified kappa statistics. |
During the initial expert evaluation, before participant recruitment for the main validation study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Internal Consistency of the KSS-UI
Time Frame: Baseline (single assessment session; approximately 15-20 minutes).
|
The internal consistency of the KSS-UI will be evaluated using Cronbach's alpha coefficient and corrected item-total correlations. The contribution of individual items to scale reliability will also be examined. |
Baseline (single assessment session; approximately 15-20 minutes).
|
|
Item Discrimination and Item Performance of the KSS-UI
Time Frame: Baseline (single assessment session; approximately 15-20 minutes).
|
Item performance will be evaluated by examining item distributions, floor and ceiling effects, and corrected item-total correlations. Item discrimination will be assessed by comparing item scores between the upper and lower 27% of participants based on total scale scores. |
Baseline (single assessment session; approximately 15-20 minutes).
|
Collaborators and Investigators
Investigators
- Principal Investigator: Esra BAYRAMOĞLU DEMİRDÖĞEN, Kırşehir Eğitim ve Araştırma Hastanesi
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- KAEU-EBAYRAMOGLUD-010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be shared to protect participants' privacy and confidentiality, given the sensitive nature of urinary incontinence-related health information. Study findings will be reported in aggregate form.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.